ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

U.S. Charges Bristol-Myers Executive With Insider Trading

By Peter Loftus Federal authorities arrested a Bristol-Myers Squibb Co. (BMY) executive Thursday on charges that he used inside information about the drug maker's acquisition targets to make more than $300,000 in illicit profits from stock-option trading. The U.S. Attorney's Office in New Jersey charged Robert Ramnarine, the drug maker's assistant treasurer for capital markets, with three counts of insider trading. Bristol-Myers issued a statement Thursday saying Mr. Ramnarine has been placed on administrative leave effective immediately. "Bristol-Myers Squibb has clear and strict policies prohibiting trading on material non-public information and is cooperating with the government's investigation," the company said. Mr. Ramnarine, of East Brunswick, N.J., allegedly purchased options in three companies that Bristol was targeting: ZymoGenetics Inc., Pharmasset Inc. and Amylin Pharmaceuticals Inc. (AMLN). Bristol-Myers purchased ZymoGenetics for $829 million in 2010 and agreed in June to acquire Amylin for $5.3 billion. Gilead Sciences Inc. (GILD) acquired Pharmasset for $11 billion earlier this year. Mr. Ramnarine served as director and executive director of pensions and savings investments at Bristol-Myers from 2008 until July 2012, when he was named to assistant treasurer of capital markets, according to a criminal complaint filed against Mr. Ramnarine in U.S. District Court in New Jersey. The complaint said Mr. Ramnarine was involved in evaluating potential Bristol-Myers acquisition targets in those roles, and had a duty not to use material, non-public information for his personal benefit. According to the complaint, Bristol-Myers began negotiating with ZymoGenetics about a deal in May 2010, and announced an agreement in September 2010. Before the public announcement, Mr. Ramnarine purchased ZymoGenetics call options, which he sold after the announcement for a profit of $30,551, according to the complaint. Bristol-Myers also explored a potential acquisition of Pharmasset in October and November of 2011 before withdrawing from discussions, which cleared the way for Gilead's acquisition, according to the complaint. Before the November announcement of the Gilead purchase of Pharmasset, Mr. Ramnarine purchased Pharmasset call options that eventually netted him about $225,026 in illicit profits, the complaint said. According to the complaint, Bristol-Myers made a preliminary offer to acquire Amylin for $25 to $27 per share in May, ultimately agreeing to pay $31 per share in June. Before the public announcement, Mr. Ramnarine purchased Amylin options that resulted in profits of $55,784, according to the complaint. Mr. Ramnarine is in custody and scheduled to make an initial court appearance in federal court in Newark, N.J., Thursday afternoon. A call to a phone listing for a Robert Ramnarine of East Brunswick, N.J., wasn't immediately returned. Write to Peter Loftus at peter.loftus@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
04/23/201417:02:14MARKET SNAPSHOT: U.S. Stocks Tumble; S&P 500 Ends 6-day Run
04/23/201415:47:47MARKET SNAPSHOT: U.S. Stocks Drift Lower
04/23/201410:40:12MARKET SNAPSHOT: U.S. Stocks Fall; PMI, Home Sales Disappoint
04/23/201410:15:39MARKET SNAPSHOT: U.S. Stocks Fall; PMI Slips In April
04/23/201409:34:30U.S. Hot Stocks: Hot Stocks to Watch
04/23/201408:45:47U.S. Stock Futures Hover Near Record
04/22/201417:30:11Gilead Sciences' Results Boosted by Hepatitis C Drug--2nd Update
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/15/201413:30:03Sales of Johnson s New Hepatitis Drug Soars
04/11/201416:32:17MARKET SNAPSHOT: U.S. Stocks Extend Fall; S&P On Pace For 2...
04/10/201409:43:48Merck: Hepatitis C Drug Shows 98% Cure Rate in Mid-Stage Trial...
04/07/201409:55:50U.S. Hot Stocks: Hot Stock to Watch
04/07/201409:25:35Gilead Hepatitis C Treatment Designated for FDA Priority Review
04/02/201418:00:08Gilead Says Hepatitis C Drug's Trial in Japan Meets Endpoint
03/30/201408:46:34MARKET SNAPSHOT: Play-it-safe Stock Investors May Take Some Risk...
03/28/201419:33:49MARKET SNAPSHOT: U.S. Stocks End Week With Losses
03/28/201415:03:35MARKET SNAPSHOT: U.S. Stocks Pare Gains; Indexes Set For Weekly...
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/24/201415:29:56MARKET SNAPSHOT: U.S. Stocks Drift Lower After Weak PMI
03/21/201416:22:49U.S. Stocks Edge Lower

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad